freeze-thaw is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | 31 amino acid residues |
| Molecular formula | C187H291N45O59 | free peptide, no counter-ion |
| Approximate mass | 4114 Da | matches theoretical value |
| Receptor target | Glucagon-like peptide-1 receptor | Gs-coupled, cyclic AMP pathway |
| Circulation half-life | About one week in humans | extended by albumin association |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
=== T-cell hypothesis === Populations of regulatory T cells are believed to be responsible for the onset of the disease. When there is a decline of these cells, manifestations of diseases begin to appear, giving an idea of the vital role of these cells in the prevention of autoimmune diseases. Moreover, an additional decrease could, unfortunately, worsen the pathological state and lead to the differentiation of an undifferentiated connective tissue disease into a differentiated connective tissue disease with a poorer prognosis. Due to the wide range of variation in the inclusion criteria of the disease, up to 50% of patients diagnosed with connective tissue disease may have undifferentiated disease of the underlying connective tissue.
zone melting Any of several methods of purifying crystalline solids which involve applying heat to a small region of a larger solid (particularly a metal ingot) until localized melting occurs, creating a molten zone which is then slowly moved along the surface to other parts of the solid by moving the target of the heating element. As it moves, the forward edge of the molten zone continuously melts new areas of impure solid, while leaving a path of purer solid behind it as previously melted areas are cooled and resolidified; because the molten liquid phase can hold a higher concentration of impurities than the solid phase, the impurities of melted areas tend to concentrate in the molten zone and be carried along as it moves, leaving behind regions with fewer impurities. The process is commonly used in the refinement of high-purity metalloids for use in semiconductors.
=== 1980–2009: Expansion globally === As the Japanese economy worsened in the 1980s, Ajinomoto sought to outsource more of its production overseas, which increased the number of employees the company employed overseas from 4,000 in 1979 to more than 11,000 in 1996. Starting in 1980, Ajinomoto began to refocus its diversification efforts from food products to its amino acid business. Following the US FDA's re-approval of aspartame in 1981, Ajinomoto began producing the sweetener at its Tokai factory in 1982. In 1987, Ajinomoto began researching drug development in the fields of clinical nutrition, anti-cancer drugs, infectious diseases, and cardiovascular drugs. Through this research, the company developed ELENTAL for use in clinical nutrition, LIVACT to fight liver disease, and Lentinan in collaboration with the Japanese Foundation for Cancer Research. Ajinomoto later released JINO as a cosmetic and amino acid for athletes, followed by Amino Vital, a supplement to JINO released in 1995. In 2000, Ajinomoto acquired NutraSweet and Euro-Aspartame from Monsanto. In December 1995, Ajinomoto's Philippine CEO and President Leonardo K. Ty was assassinated by two members of the communist guerrilla group Alex Boncayao Brigade. The group cited Ty's allegedly poor safety standards for one of his other companies that they claimed to have led to the deaths of several of his employees. Ty had been head of Union Ajinomoto Inc. with his brother Alejandro since the late 1960s, and prior to his death, Ty had been seeking the protection of the National Bureau of Investigation.
Sources: en.wikipedia.org
== General characteristics == Stichodactyla helianthus is a tropical anemone commonly known as the “Sun Anemone” and part of the order Actiniaria, which comprises the sea anemones of the class Anthozoa. Described posthumously by John Ellis in 1786, these organisms, like all Anthozoa, are documented by the absence of an operculum–a calcareous shell in a circular form. Anthozoans also possess circular mitochondrial DNA and siphonoglyphs (ciliated grooves) in the pharyngeal wall. Another predominant trait resides in the presence of the coelenteron around the centralized body cavity, which is divided by distinct septa. In terms of reproductive distinction, this species lacks a medusa stage and exhibits the polyp stage exclusively.
Kozak consensus sequence Also simply Kozak sequence. A highly conserved nucleic acid sequence motif which functions as the recognition site for the initiation of translation in most eukaryotic messenger RNAs, generally a sequence of 10 bases immediately surrounding and inclusive of the start codon: GCCRCCAUGG. As the pre-initiation complex scans the transcript, recognition of this sequence (or a close variant) causes the complex to commit to full ribosome assembly and the start of translation. The Kozak sequence is distinct from other recognition sequences relevant to translation such as ribosome binding sites and internal ribosome entry sites.
Factors affecting chain length and pattern distribution α-Keto acid primers are used to produce branched-chain fatty acids that, in general, are between 12 and 17 carbons in length. The proportions of these branched-chain fatty acids tend to be uniform and consistent among a particular bacterial species but may be altered due to changes in malonyl-CoA concentration, temperature, or heat-stable factors (HSF) present. All of these factors may affect chain length, and HSFs have been demonstrated to alter the specificity of BCKA decarboxylase for a particular α-keto acid substrate, thus shifting the ratio of branched-chain fatty acids produced. An increase in malonyl-CoA concentration has been shown to result in a larger proportion of C17 fatty acids produced, up until the optimal concentration (≈20μM) of malonyl-CoA is reached. Decreased temperatures also tend to shift the fatty-acid distribution slightly toward C17 fatty-acids in Bacillus species.
== Fuels and consumption == Ashing is a test to deduce the amount of ash forming material present in a petroleum product so as to decide its use in certain applications. Ash-forming materials are considered to be undesirable impurities or contaminants. In the ash analysis of petroleum products, ash content represents the incombustible component remaining after a sample of the furnace oil is completely burned. The ash content of petroleum products is generally low. It is defined as the inorganic residue that remains after combustion of the oil in air at specific high temperature. Ash typically ranges from 0.1 to 0.2% in oil. Some of the ash forming constituents occur naturally in crude oil; others are present as a result of refining or contamination during storage or distribution. Knowledge of the amount of ash-forming material present in a product can provide information as to whether or not the product is suitable application. In the ash analysis of coal and other solid fuels, the amount of sulfur retained in the ash during the ashing process is not constant, but rather is dependent upon the conditions of ashing as well as the other inorganic constituents in the ash that may form sulfates during the ashing procedure. As such, different ashing procedures may yield different ash contents.
Sources: en.wikipedia.org
== Definition == The phrase "drug design" is similar to ligand design (i.e., design of a molecule that will bind tightly to its target). Although design techniques for prediction of binding affinity are reasonably successful, there are many other properties, such as bioavailability, metabolic half-life, and side effects, that first must be optimized before a ligand can become a safe and effective drug. These other characteristics are often difficult to predict with rational design techniques. Due to high attrition rates, especially during clinical phases of drug development, more attention is being focused early in the drug design process on selecting candidate drugs whose physicochemical properties are predicted to result in fewer complications during development and hence more likely to lead to an approved, marketed drug. Furthermore, in vitro experiments complemented with computation methods are increasingly used in early drug discovery to select compounds with more favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles.
Kanury Rao also known as Kanury Venkata Subba Rao (born 1958) is an Indian immunologist. He was the head of the Drug Discovery Research Centre (DDRC) at the Translational Health Science and Technology Institute (THSTI) Faridabad. He is known for his studies in the fields of peptide synthesis and cell signaling and the design of synthetic peptide vaccines. He is an elected fellow of the Indian Academy of Sciences, National Academy of Sciences, India and the Indian National Science Academy. and a recipient of several awards including the Millennium Plaque of Honour of the Indian Science Congress and the National Bioscience Award for Career Development. The Council of Scientific and Industrial Research awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology, in 1997, for his contributions to biological sciences.
=== Longnose skate === The longnose skate, Raja rhina, is considered a larger skate species; reaching a maximum size range of 145 cm total length. Although their egg cases are smaller than that of the big skate, their cases are also considered large; ranging 93–102 mm in length. Egg cases contain a single embryo. Longnose skate egg cases found in the field are brown in color. The external side is covered with a fibrous material, which is thicker on the top side and thinner on the bottom side of the case. The case is smooth underneath the fibrous material.
The precise extent to which KOR agonism underlies ibogaine's anti-addictive properties is unclear. In animal models, ibogaine administration has been shown to reduce self-administration of opioids, stimulants, and alcohol, ameliorate withdrawal symptoms, and decrease drug-seeking behavior. A 2022 systematic review of 24 studies involving 705 participants found that both ibogaine and noribogaine show promise in treating substance use disorders and comorbid depressive symptoms.
==== Cisplatin-resistance ==== The drug paclitaxel may be useful in the treatment of cisplatin-resistant cancer. About 68.1% of cisplatin-resistant cells appear to be sensitive to paclitaxel and 66.7% of paclitaxel-resistant cells to cisplatin. The mechanism for this activity is unknown. Paclitaxel-based chemotherapy showed modest activity in SCLC patients refractory to both etoposide- and camptothecin-based chemotherapy. The newer agent lurbinectedin is active in relapsed SCLC and was approved for medical use in the United States in June 2020.
Sources: en.wikipedia.org
It is a synthetic peptide of 31 amino acids, built to resemble the natural incretin hormone GLP-1. Because of its size and composition it is handled analytically like other therapeutic peptides, using chromatographic and mass spectrometric methods rather than the techniques typical of small organic drugs.
The substitution at position 8 removes the site recognised by dipeptidyl peptidase-4, the enzyme that destroys the native hormone within minutes. The linked lipophilic chain then binds circulating albumin, which further limits access by degradative enzymes and reduces renal loss. Together these features lengthen the effective circulation time considerably.
It acts at the glucagon-like peptide-1 receptor, a G protein-coupled receptor that signals mainly through cyclic AMP. Activation is glucose dependent, meaning insulin release is stimulated more strongly when blood glucose is already elevated. Other tissues carrying the same receptor respond as well, which explains effects beyond glucose control.
Long-term storage is usually at minus 20 to minus 80 degrees Celsius in a sealed, desiccated container. Working aliquots can be held briefly at 2 to 8 degrees Celsius.